A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer

E. Vasile, G. Masi, L. Fornaro, S. Cupini, F. Loupakis, S. Bursi, I. Petrini, S. Di Donato, I. M. Brunetti, S. Ricci, A. Antonuzzo, S. Chiara, D. Amoroso, M. Andreuccetti, A. Falcone

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The triple drug combination consisting of irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) has demonstrated higher activity and efficacy compared to the doublet FOLFIRI. 5-Fluorouracil could be substituted in FOLFOXIRI regimen by capecitabine, an oral fluoropyrimidine with similar efficacy. Recently, a dose-finding trial has demonstrated the feasibility of the combination of irinotecan, oxaliplatin and capecitabine (XELOXIRI) and established their recommended doses. The aim of this study was to evaluate the activity of XELOXIRI. A total of 36 patients with unresectable metastatic colorectal cancer received irinotecan 165 mg m 2 and oxaliplatin 85 mg m 2 on day 1 plus capecitabine 2000 mg m 2 per day orally in two doses from day 1 to day 7, every 2 weeks. Grade 3-4 toxicities were infrequent, expect for neutropenia and diarrhoea, which were each observed in 30% of patients. Two complete and twenty-two partial responses were obtained, corresponding to an overall response rate of 67% (95% CI 51.4-82%). After a median follow-up of 17.7 months, the median progression-free and overall survival were 10.1 and 17.9 months, respectively.The substitution of 5-fluorouracil with capecitabine, in combination with irinotecan and oxaliplatin, is feasible and does not impair the activity of the regimen. However, the XELOXIRI combination is associated with a high incidence of diarrhoea and, therefore, should be considered as a not preferable alternative to FOLFOXIRI.

Original languageEnglish
Pages (from-to)1720-1724
Number of pages5
JournalBritish Journal of Cancer
Volume100
Issue number11
DOIs
Publication statusPublished - Jun 2 2009

Fingerprint

oxaliplatin
irinotecan
Colorectal Neoplasms
Fluorouracil
Diarrhea
Drug Combinations
Therapeutics
Neutropenia
Disease-Free Survival
capecitabine-irinotecan combination
Incidence

Keywords

  • First-line treatment
  • Metastatic colorectal cancer
  • Triple drug combination
  • XELOXIRI

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. / Vasile, E.; Masi, G.; Fornaro, L.; Cupini, S.; Loupakis, F.; Bursi, S.; Petrini, I.; Di Donato, S.; Brunetti, I. M.; Ricci, S.; Antonuzzo, A.; Chiara, S.; Amoroso, D.; Andreuccetti, M.; Falcone, A.

In: British Journal of Cancer, Vol. 100, No. 11, 02.06.2009, p. 1720-1724.

Research output: Contribution to journalArticle

Vasile, E, Masi, G, Fornaro, L, Cupini, S, Loupakis, F, Bursi, S, Petrini, I, Di Donato, S, Brunetti, IM, Ricci, S, Antonuzzo, A, Chiara, S, Amoroso, D, Andreuccetti, M & Falcone, A 2009, 'A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer', British Journal of Cancer, vol. 100, no. 11, pp. 1720-1724. https://doi.org/10.1038/sj.bjc.6605075
Vasile, E. ; Masi, G. ; Fornaro, L. ; Cupini, S. ; Loupakis, F. ; Bursi, S. ; Petrini, I. ; Di Donato, S. ; Brunetti, I. M. ; Ricci, S. ; Antonuzzo, A. ; Chiara, S. ; Amoroso, D. ; Andreuccetti, M. ; Falcone, A. / A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. In: British Journal of Cancer. 2009 ; Vol. 100, No. 11. pp. 1720-1724.
@article{d1ad5d9f62d64647b3b3379f60cd9081,
title = "A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer",
abstract = "The triple drug combination consisting of irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) has demonstrated higher activity and efficacy compared to the doublet FOLFIRI. 5-Fluorouracil could be substituted in FOLFOXIRI regimen by capecitabine, an oral fluoropyrimidine with similar efficacy. Recently, a dose-finding trial has demonstrated the feasibility of the combination of irinotecan, oxaliplatin and capecitabine (XELOXIRI) and established their recommended doses. The aim of this study was to evaluate the activity of XELOXIRI. A total of 36 patients with unresectable metastatic colorectal cancer received irinotecan 165 mg m 2 and oxaliplatin 85 mg m 2 on day 1 plus capecitabine 2000 mg m 2 per day orally in two doses from day 1 to day 7, every 2 weeks. Grade 3-4 toxicities were infrequent, expect for neutropenia and diarrhoea, which were each observed in 30{\%} of patients. Two complete and twenty-two partial responses were obtained, corresponding to an overall response rate of 67{\%} (95{\%} CI 51.4-82{\%}). After a median follow-up of 17.7 months, the median progression-free and overall survival were 10.1 and 17.9 months, respectively.The substitution of 5-fluorouracil with capecitabine, in combination with irinotecan and oxaliplatin, is feasible and does not impair the activity of the regimen. However, the XELOXIRI combination is associated with a high incidence of diarrhoea and, therefore, should be considered as a not preferable alternative to FOLFOXIRI.",
keywords = "First-line treatment, Metastatic colorectal cancer, Triple drug combination, XELOXIRI",
author = "E. Vasile and G. Masi and L. Fornaro and S. Cupini and F. Loupakis and S. Bursi and I. Petrini and {Di Donato}, S. and Brunetti, {I. M.} and S. Ricci and A. Antonuzzo and S. Chiara and D. Amoroso and M. Andreuccetti and A. Falcone",
year = "2009",
month = "6",
day = "2",
doi = "10.1038/sj.bjc.6605075",
language = "English",
volume = "100",
pages = "1720--1724",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer

AU - Vasile, E.

AU - Masi, G.

AU - Fornaro, L.

AU - Cupini, S.

AU - Loupakis, F.

AU - Bursi, S.

AU - Petrini, I.

AU - Di Donato, S.

AU - Brunetti, I. M.

AU - Ricci, S.

AU - Antonuzzo, A.

AU - Chiara, S.

AU - Amoroso, D.

AU - Andreuccetti, M.

AU - Falcone, A.

PY - 2009/6/2

Y1 - 2009/6/2

N2 - The triple drug combination consisting of irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) has demonstrated higher activity and efficacy compared to the doublet FOLFIRI. 5-Fluorouracil could be substituted in FOLFOXIRI regimen by capecitabine, an oral fluoropyrimidine with similar efficacy. Recently, a dose-finding trial has demonstrated the feasibility of the combination of irinotecan, oxaliplatin and capecitabine (XELOXIRI) and established their recommended doses. The aim of this study was to evaluate the activity of XELOXIRI. A total of 36 patients with unresectable metastatic colorectal cancer received irinotecan 165 mg m 2 and oxaliplatin 85 mg m 2 on day 1 plus capecitabine 2000 mg m 2 per day orally in two doses from day 1 to day 7, every 2 weeks. Grade 3-4 toxicities were infrequent, expect for neutropenia and diarrhoea, which were each observed in 30% of patients. Two complete and twenty-two partial responses were obtained, corresponding to an overall response rate of 67% (95% CI 51.4-82%). After a median follow-up of 17.7 months, the median progression-free and overall survival were 10.1 and 17.9 months, respectively.The substitution of 5-fluorouracil with capecitabine, in combination with irinotecan and oxaliplatin, is feasible and does not impair the activity of the regimen. However, the XELOXIRI combination is associated with a high incidence of diarrhoea and, therefore, should be considered as a not preferable alternative to FOLFOXIRI.

AB - The triple drug combination consisting of irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) has demonstrated higher activity and efficacy compared to the doublet FOLFIRI. 5-Fluorouracil could be substituted in FOLFOXIRI regimen by capecitabine, an oral fluoropyrimidine with similar efficacy. Recently, a dose-finding trial has demonstrated the feasibility of the combination of irinotecan, oxaliplatin and capecitabine (XELOXIRI) and established their recommended doses. The aim of this study was to evaluate the activity of XELOXIRI. A total of 36 patients with unresectable metastatic colorectal cancer received irinotecan 165 mg m 2 and oxaliplatin 85 mg m 2 on day 1 plus capecitabine 2000 mg m 2 per day orally in two doses from day 1 to day 7, every 2 weeks. Grade 3-4 toxicities were infrequent, expect for neutropenia and diarrhoea, which were each observed in 30% of patients. Two complete and twenty-two partial responses were obtained, corresponding to an overall response rate of 67% (95% CI 51.4-82%). After a median follow-up of 17.7 months, the median progression-free and overall survival were 10.1 and 17.9 months, respectively.The substitution of 5-fluorouracil with capecitabine, in combination with irinotecan and oxaliplatin, is feasible and does not impair the activity of the regimen. However, the XELOXIRI combination is associated with a high incidence of diarrhoea and, therefore, should be considered as a not preferable alternative to FOLFOXIRI.

KW - First-line treatment

KW - Metastatic colorectal cancer

KW - Triple drug combination

KW - XELOXIRI

UR - http://www.scopus.com/inward/record.url?scp=67349088298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349088298&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6605075

DO - 10.1038/sj.bjc.6605075

M3 - Article

C2 - 19436300

AN - SCOPUS:67349088298

VL - 100

SP - 1720

EP - 1724

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 11

ER -